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Abstract 
The role of cytogenetics in identification of double-
hit lymphoma, a subset of a high grade large B-cell 
lymphoma. 
KEYWORDS 
Diffuse large B-cell lymphoma; double-hit 
lymphoma; triple-hit lymphoma; MYC; BCL2; 
BCL6. 
Identity 
Double Hit Lymphoma (DHL) 
Triple Hit Lymphoma (THL) 
Note 
The "double-hit" lymphoma is a genotype feature of 
lymphoma that exhibits translocations of both the 
MYC /8q24 gene and a second site, most often the 
BCL2/18q21 or less commonly the BCL6/3q27 
gene. A rare "triple-hit" lymphoma harboring MYC, 
BCL2, and BCL6 translocations has also been 
identified. Cytogenetics is necessary in establishing 
the diagnosis of these lymphomas as they tend to 
manifest an aggressive behavior, and poor outcome 
when treated with standard therapy. 
Clinics and pathology 
Disease 
Double-hit lymphoma (DHL), triple-hit lymphoma 
(THL), diffuse large B-cell lymphoma (DLBCL), 
high grade B-cell lymphoma (HGBL) with MYC, 
BCL2 and/or BCL6 rearrangements 
Epidemiology 
The DH lymphoma most commonly affects elderly 
patients with a median age of 62-74 years (range 18-
96 years), and both sexes are affected with a slight 
male predominance. The incidence of DH genotype 
has been difficult to assess because fluorescence in 
situ hybridization (FISH) studies have not been used 
widely on unselected series, and the published data 
may be biased toward a specific type of lymphoma. 
Nevertheless, DH lymphoma has been reported in 5-
15% of patients with DLBCL and aggressive B-cell 
lymphoma. Comprehensive analysis of Mitelman 
Database of Chromosome Aberrations in Cancer 
(Aukema et al, 2011, Oliveira et al 2017), DH 
lymphomas with breaks at MYC, BCL2 and/or 
BCL6 regions were identified in 14% of DLBCL 
cases; 62% of those involved MYC and BCL2 sites, 
18% involved MYC and BCL6 while the remaining 
cases had triple translocations. Using FISH, Barrans 
et al (2010) identified DH and TH genotypes in 12% 
cases with de novo DLBCL; the majority of these 
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cases had BCL2 and MYC translocations (66%), 
BCL6 and MYC breaks in 10% and breaks in all 
three sites in 24% of cases. MYC and BCL2 
translocations are also found in a small proportion of 
follicular lymphoma. We identified MYC breaks in 
7% of t(14;18)-bearing follicular lymphoma cases; 
all described to have a high grade morphology with 
Burkitt-like or blastic morphology replacing residual 
follicles (Mohamed et al, 2001).  Pedersen et al have 
reported that in transformed lymphoma, DH 
genotype was very frequent found in 21% of cases; 
all had follicular lymphomas (Pedersen et al 2012). 
Clinics 
Patients with DH lymphomas commonly have an 
aggressive clinical course, characterized by 
advanced stage disease, extranodal involvement, and 
high serum lactate dehydrogenase levels.  The 
extranodal sites include the bone marrow, central 
nervous system, gastrointestinal tract, liver, spleen, 
lung, pleural fluid, testis, ovaries, skin, and thyroid 
gland. Bone marrow is involved in about 50% of 
patients and many have a leukemic disease. The 
International Prognostic Index score (IPI score) is 
often intermediate-high or high (Barrans et al 2010, 
Petrich et al 2014). Most patients have a de novo 
disease while a minority (10%) present with a history 
of a low-grade follicular lymphoma or other B-cell 
lymphoma, then develop DHL presumably by the 
acquisition of MYC rearrangement.  
 
 Double Expresser lymphoma    
Immunohistochemistry (IHC) has identified a 
fraction of DLBCL cases with high expression of 
MYC and BCL2 proteins (Perry et al 2014, 
Mahmoud et al 2015). These double expresser 
lymphomas (DE) are lacking MYC and BCL2 
translocations and are usually of non-GC types. DE 
lymphomas are much more common than DH 
lymphomas, with approximately 30% of DLBCL 
being reported as DE lymphomas. Most studies use 
a cutoff of 40% for MYC IHC and a cutoff of 70% 
for BCL2 to define DE lymphoma (Green et al 2012 
A). Clinically, the DE lymphomas have more 
aggressive clinical course than those lacking MYC 
and BCL2 protein expression. 
Pathology 
Because DHL is genotypically defined; it is not 
restricted to a specific histology subtype. Most 
tumors are medium to large in size, with atypical 
morphology and very high proliferation rate.  
Previously, DH lymphomas were diagnosed as 
diffuse large B-cell lymphoma (DLBCL), aggressive 
B-cell lymphoma not otherwise specified (NOS) or 
Burkitt-like lymphoma. Rare cases were classified as 
lymphoblastic lymphoma. The increase recognition 
of these lymphomas led the 2008 WHO 
classification of hematopoietic and lymphoid 
neoplasms to introduce a provisional category of "B-
cell lymphoma, unclassifiable, with features 
intermediate between DLBCL and BL", (BCLU) to 
recognize a subset of very aggressive lymphoma in 
which the distinction between DLBCL and BL is 
difficult (Campo et al 2011, Swerdlow et al 2014).  
The 2008 WHO criteria were somewhat subjective 
and vaguely defined; as a result, recent studies have 
not been consistent with survival and disease 
outcome. Therefore, separation of these cases has 
become necessary to better define these clinically 
aggressive tumors.  In the revised 2016 WHO 
classification of lymphoid neoplasms, all LBCL with 
"double hit" and "triple hit" genotype are included in 
a single category of "high-grade B-cell lymphomas 
(HGBL) with MYC and BCL2 and/or BCL6 
rearrangements" (Swerdlow et al, 2016).  
 
 Immunophenotype   
Most double hit lymphomas have a germinal center 
(GC) phenotype with expression of CD10 and BCL6 
and lack of MUM1/IRF4. Expression of BCL2 
protein is detected in almost 95% of cases supporting 
the observation that the BCL2 translocation is 
mainly found in GC type of DLBCL, and also MYC 
translocations are associated with a GC molecular 
profile in DLBCL.  The proliferation index as 
measured by Ki67 immunohistochemical staining is 
often high (>90%).  Therefore, although not very 
specific, co-expression of CD10, BCL6, BCL2, and 
a high Ki67 may predict double hit genotype in 
tumors morphologically diagnosed as DLBCL 
(Aukema et al 2011, Swerdlow et al 2014). 
Treatment 
Standard therapies such as R-CHOP developed for 
patients with DLBCL are less effective in DHL, with 
a median overall survival of 12 months or less, as the 
majority of patients experience disease progression.  
Currently, more, intensive chemotherapy such as 
dose adjusted R-EPOCH therapy, is being evaluated 
which appears to be effective in many DH 
lymphoma patients. Consideration for frontline stem 
cell transplant in responding patients are also 
suggested (Oki et al 2014, Petrich et al 2014, 
Dunleavy 2015). 
Prognosis 
Patients with classic, FISH-defined DH lymphomas 
have a very poor prognosis, usually present with 
high clinical risk factors, such as high IPI scores and 
bone marrow involvement. The outcome is dismal 
with rare long term survival after standard therapy 
(Perry et al 2014, Petrich et al 2014, Oki et al 2014).  
Several recent studies have indicated that the 





Atlas Genet Cytogenet Oncol Haematol. 2018; 22(4) 144 
 
outcome of DE lymphomas, as defined by IHC is 
inferior to that of DLBCL but better than that of DH 
lymphomas. Therefore, the co-expression of MYC 
and BCL2 proteins in DLBCL is considered a 
prognostic biomarker of an inferior outcome (Green 




t(3;14)(q27;q32) and variants. 
 
Figure 1:  Complex karyotype from a double hit lymphoma showing t(14;18)(q32;q21) and add(8)(q24) 
Cytogenetics morphological 
Double-hit lymphomas are usually seen in the 
context of a complex karyotype containing multiple 
numerical and structural aberrations (Figure 1). Over 
2/3 of cases demonstrate dual translocations 
involving 8q24/MYC and t(14;18)/BCL2 
breakpoints. Less commonly the translocations 
implicate 8q24/MYC and 3q27/BCL6 sites and rare 
cases have breaks in all three sites, referred to a 
"triple hit" lymphoma. The partner gene(s) involved 
in MYC/8q24 translocations are the IG genes in 
about of 60% of DHL cases; more frequently 
affecting the IG light chain loci 22q12/IG lambda 
and 2p12/IG kappa loci than the heavy chain 
14q32/IGH (Aukema et al 2011, Swerdlow et al 
2014). Non-IG partners are found in 40%, 
recurrently involved 19p13, 1q24, 9p13, or non-
identified partner regions (Figure 1). Deletions of 
chromosome 17p13/ TP53 are present in 20-30% of 
cases, which can further induce genomic instability, 
and contribute to the aggressive course of the disease 
(Figure 1). 
Cytogenetics molecular 
Conventional cytogenetics is not always feasible 
since fresh tissue is required, and small 
translocations can be overlooked in a complex 
karyotype. Therefore, most cases currently are 
detected by FISH using labeled probes targeting 
genes of interest. FISH studies can be successfully 
performed with high reproducibility in almost all 
cases using formalin-fixed paraffin-embedded tissue 
sections, although smears, touch imprints, or pellet 
of metaphase and interphase cells can also be used. 
Today, most clinical cytogenetic laboratories are 
using a panel of FISH probes for detection of double 
hit lymphomas including LSI MYC break-apart 
(BA), LSI BCL6 BA, and LSI IGH-BCL2 dual 
fusion translocation probes. The IGH-MYC dual 
fusion translocation probe is useful in picking up 
occasional cases missed by the MYC BA probe and 
also in identifying the MYC partner in a subset of the 
cases (Figure 2 B). Collectively, FISH is considered 
the "Gold-Standard" test in identifying DH and TH 
lymphomas. At present it is a subject of debate, if all 
DLBCL should have FISH testing to detect MYC, 
BCL2, and BCL6 rearrangements or should FISH 
only performed on selected cases with high grade 
morphology and CG phenotypes. Guidelines are 
warranted to avoid high cost and at the same time not 
miss those aggressive lymphomas (Pedersen et al 
2012, Sesques and Johnson 2017). 
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Figure 2:  FISH panel for "double-hit" lymphoma, 
A; MYC BA probe set showing a split/translocation 
pattern. B; IGH/MYC,CEP8 tricolor dual fusion 
translocation probe set showing two fusion signals 
indicating the presence oft(8;14). C; IGH/BCL2 dual 
fusion translocation probe set showing two fusion 
signals indicating t(14;18). D; BCL6 BA probe set 
showing a split/translocation pattern (all probes 
purchased from Abbott Molecular Inc, Des Plaines, 
IL USA). 
Genes involved and 
proteins 
MYC v-myc myelocytomatosis viral 




Alternative symbols: MYC proto-oncogene, bHLH 
transcription factor, v-myc avian myelocytomatosis 
viral oncogene homolog. 
Protein 
The product of the MYC gene has a molecular mass 
of 65 kD, is located predominantly in the nucleus, 
and binds to DNA. It is a multifunctional, nuclear 
phosphoprotein that plays a role in cell cycle 
progression, metabolism, DNA repair, apoptosis and 
cellular transformation. MYC operates as a 
transcription factor, being involved in almost every 
aspect of cell biology. It has been reported to 
regulate the expression of almost 15% of genes 
within the human genome. Over expression of MYC 
is associated with uncontrolled cell growth and 
metastasis whereas loss of its expression delays 
growth and promotes differentiation. Some of the 
most biologically important MYC target genes are 
cyclins and cyclin-dependent kinases (CDKs), 
resulting in accelerated cell cycling. Additionally, 
MYC is involved in the regulation of many micro-
RNA (miRNA) expressions, including both the 
tumor suppressor and the oncogenic miRNAs 
(Aukema et al 2011, Sesques et al 2017). MYC 
induces DNA stress and activates the TP53 
checkpoint, leading to apoptosis (Hoffman and 
Liebermann 2008). 




Alternative symbol: Apoptosis regulator; B-cell 
leukemia/lymphoma 2. 
Protein 
BCL2 protein is the most potent member of a large 
BCL2 family which regulate cell death (apoptosis), 
by either inducing pro-apoptotic proteins or 
inhibiting apoptosis. BCL2 is widely expressed in 
immature B cells and memory B cells but is down-
regulated in GC B cells, partially because of 
repression by BCL6. It is localized to the outer 
membrane of mitochondria, where it plays an 
important role in promoting cellular survival and 
inhibiting the actions of pro-apoptotic proteins. The 
pro-apoptotic proteins in the BCL-2 family, 
including BAX and BAK1, normally act on the 
mitochondrial membrane to promote 
permeabilization and release of cytochrome C and 
ROS1 that are important signals in the apoptosis 
cascade. These pro-apoptotic proteins are inhibited 
by the function of BCL2. 




Alternative symbols: B-cell lymphoma 6; Zinc 
finger protein 51 (ZNF51). 
Protein 
The protein encoded by this gene is a zinc finger 
transcription factor and contains an N-terminal POZ 
domain. This protein acts as a sequence-specific 
repressor of transcription, and has been shown to 
modulate the transcription of STAT-dependent IL-4 
responses of B cells. It can interact with a variety of 
POZ-containing proteins that function as 
transcription corepressors. BCL6 functions as a 
transcriptional repressor of many target genes 
involved in apoptosis, DNA damage response, cell 
cycle control, proliferation, and differentiation. 
These genes are BCL2, TP53, IRF4, and PRDM1 
(BLIMP1), the latter being essential for maturation 
into plasma cells. As a result of the BCL6-mediated 
repression of TP53, somatic hypermutation and class 
switch recombination are facilitated. Approximately 
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30% of diffuse large cell lymphomas and 10% of 
follicular lymphomas have 3q27 chromosomal 
translocations that upregulate expression of BCL6 
by juxtaposing to IG or non-IG promoters to the 
BCL6 coding domain.  
BCL6 is widely expressed in many tissues, but in B-
cells it is mostly restricted to germinal center B cells. 
The expression of BCL6 can be demonstrated in 
tissue sections by IHC. It is present in B-cells of both 
healthy and neoplastic germinal centers. It therefore 
demonstrates both reactive hyperplasia in lymph 
nodes and a range of lymphomas derived from 
follicular B-cells, such as Burkitt's lymphoma, 
follicular lymphoma, and the nodular lymphocyte 
predominant subtype of Hodgkin's disease. It is often 
used together with antibodies to Bcl-2 antigen to 
distinguish neoplastic follicles from those found in 
benign hyperplasia, for which Bcl-2 is negative. 




MYC translocations, a biological hallmark of BL, 
can also be detected in other B-cell lymphomas 
DLBCL, BCLU, and FL but at lower frequencies 
(mohamed et al 2001). However, there are some 
fundamental differences between MYC 
translocation in BL and in other mature B-cell 
lymphomas. In BL the MYC translocation always 
involves one of the IG genes, (IGH, IGL or IGK) and 
is considered a disease-initiating event which occurs 
in the context of a rather simple karyotype (Dave et 
al 2006). In contrast, MYC translocations in other 
mature B-cell lymphomas frequently involve non-IG 
partners and are mostly found in complex 
karyotypes, often in addition to well-known primary 
aberrations such as t(14;18) or t(3;14) translocation. 
In these lymphomas, MYC translocation is 
considered as a secondary event occurs during 
disease progression. Dave et al reported that the gene 
expression of MYC translocations in BL tend to be 
simple and control several genes involved in 
proliferation. In contrast, MYC aberrations in 
DLBCL-targeted genes are associated with nuclear 
factor kB (NF-kB) signaling and antiapoptotic 
cascades. Other mechanisms of MYC deregulation 
in aggressive B-cell lymphomas are mutations, 
increase copy number and transcriptional 
upregulation, mainly by B-cell receptor and NF-kB 
signaling.  Recent studies show that microRNAs 
may upregulate MYC expression.  In clinical setting, 
MYC aberrations can be detected by conventional 
cytogenetics, FISH, and recently by IHC.  
 
In t(14;18) follicular lymphoma, the transcription of 
BCL2 is "constitutively" upregulated that leads to a 
survival advantage of the involved B cells. BCL2 
overexpression in B cells also leads to impaired 
DNA repair by blocking nonhomologous end-
joining activities of Ku proteins essential for repair 
of both RAG1 / RAG2 - and AICDA -mediated 
breakpoints. The t(14;18) is thought to occur early in 
B-cell development however, it is insufficient to 
cause follicular lymphoma because t(14;18) is rarely 
observed as a sole karyotypic abnormality 
(Mohamed et al 2001) and also can be found in 
mature B cells in healthy individuals. The over-
expression of BCL2 makes the cells susceptible for 
additional genomic alterations such as MYC or 
BCL6 mutation and rearrangement.  BCL2 protein is 
detected in over 50% of DLBCL and in 75% of 
HGBL, but is not expressed in BL. 
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